Richard A. Young - 28 Jun 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
28 Jun 2024
Net transactions value
-$178,365
Form type
4
Filing time
02 Jul 2024, 16:15:03 UTC
Previous filing
21 Jun 2024
Next filing
18 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Sale $178,365 -34,837 -81% $5.12 8,000 28 Jun 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 29, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.